[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paramedian-forehead-flap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paramedian-forehead-flap":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100526042","phase-1-topical-cbd-scar-healing-study-100526042",false,"NCT06129591","Topical CBD Scar Healing Study","The Effects of Topical Cannabidiol on Paramedian Forehead Flap Scar Healing: A Split Scar Study (TOPSCAR)","Inclusion Criteria\n\n* Patients that are adults (18+) of all genders and ethnicities who have undergone a PMFF (Paramedian forehead flap) will be considered for this study.\n* English-speaking patients\n\nExclusion Criteria\n\n* Patients younger than 18 years of age\n* Non-English speaking patients\n* Patients with known allergies to CBD\n* Pregnant women\n* Prisoners\n* Patients with moderate to severe hepatic impairment\n* A history of suicidal ideation and behavior within the last 6 months\n* Patients with severe depression\n* Who anticipate coadministration of other CNS depressants including alcohol that could potentiate the sedating effects of the drug\n* Patients with a history of severe hypersensitivity reactions to adhesives\n* Patients who anticipate coadministration of potentially hepatotoxic drugs\n* Patients who anticipate coadministration of sensitive CYP2C19 substrates per labeling\n\nTermination criteria\n\n* There will be immediate termination from the study if any allergic response to the CBD\u002Fsilicone combination occurs or if the topical application of CBD\u002Fsilicone significantly worsens the scar outcome at the Follow Up 2 visit or at any subsequent visit.\n* Subject will not receive any additional CBD doses if they experience an adverse event assessed as ≥ Grade 3 (including hepatotoxicities and hematologic adverse events, ≥ Grade 2 for the system-organ class of Cardiac Disorders) according to CTCAE v5. They will remain on study in follow-up until the adverse event resolves or stabilizes.\n* If the patient voluntarily requests cessation in the study.\n* Pregnancy\n* Increase in serum transaminases (ALT\u002FAST) to above three times the upper limit of normal or increase in total bilirubin to above two times the upper limit of normal.\n* If a subject experiences worsening depression or suicidal ideation or behavior, the participant will be discontinued from treatment with CBD and immediately referred to a mental health professional. The decision to resume treatment with CBD will be made in collaboration with a mental health professional.","ALL","18 Years",{"count":19,"type":20},22,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.",[26],"Paramedian Forehead Flap",[28,29,30],"CBD oil","Paramedian Forehead Flap Reconstruction","silicone patch","RECRUITING","2026-08-31",{"date":34,"type":35},"2026-09-01","ACTUAL",{"date":37,"type":20},"2026-09",{"date":39,"type":20},"2028-07",{"name":41,"class":42},"University of Oklahoma","OTHER"]